Karyopharm Therapeutics Inc. (NASDAQ:KPTI) received a $18.00 target price from equities researchers at Cantor Fitzgerald in a research report issued on Thursday. The brokerage currently has a “buy” rating on the stock. Cantor Fitzgerald’s price target points to a potential upside of 58.73% from the company’s current price.
Several other research firms also recently weighed in on KPTI. Jefferies Group LLC restated a “buy” rating and issued a $19.00 price target (up previously from $16.00) on shares of Karyopharm Therapeutics in a research note on Thursday, August 10th. BidaskClub upgraded Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, August 25th. ValuEngine downgraded Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, August 18th. Zacks Investment Research downgraded Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, July 18th. Finally, Canaccord Genuity set a $18.00 price target on Karyopharm Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, August 8th. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $15.38.
Karyopharm Therapeutics (NASDAQ KPTI) opened at 11.34 on Thursday. Karyopharm Therapeutics has a 12-month low of $6.27 and a 12-month high of $14.63. The stock has a 50 day moving average price of $10.81 and a 200-day moving average price of $9.91. The company’s market cap is $534.54 million.
Karyopharm Therapeutics (NASDAQ:KPTI) last posted its earnings results on Tuesday, August 8th. The company reported ($0.64) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.64). Karyopharm Therapeutics had a negative return on equity of 70.42% and a negative net margin of 67,267.47%. Karyopharm Therapeutics’s revenue for the quarter was down 95.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.84) EPS. On average, analysts predict that Karyopharm Therapeutics will post ($2.62) EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This article was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another site, it was illegally stolen and reposted in violation of U.S. and international copyright legislation. The original version of this article can be viewed at https://www.dispatchtribunal.com/2017/10/14/karyopharm-therapeutics-inc-kpti-given-a-18-00-price-target-by-cantor-fitzgerald-analysts.html.
In related news, Director Mansoor Raza Mirza sold 2,882 shares of the company’s stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $11.00, for a total value of $31,702.00. Following the transaction, the director now directly owns 2,882 shares of the company’s stock, valued at approximately $31,702. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold a total of 10,695 shares of company stock worth $118,950 over the last ninety days. 14.71% of the stock is currently owned by insiders.
A number of hedge funds have recently added to or reduced their stakes in the stock. Wellington Management Group LLP lifted its position in Karyopharm Therapeutics by 0.9% in the 1st quarter. Wellington Management Group LLP now owns 5,780,553 shares of the company’s stock valued at $74,223,000 after acquiring an additional 54,137 shares in the last quarter. Palo Alto Investors LLC lifted its position in Karyopharm Therapeutics by 1.8% in the 2nd quarter. Palo Alto Investors LLC now owns 3,467,575 shares of the company’s stock valued at $31,382,000 after acquiring an additional 61,100 shares in the last quarter. Vanguard Group Inc. lifted its position in Karyopharm Therapeutics by 31.1% in the 2nd quarter. Vanguard Group Inc. now owns 1,621,420 shares of the company’s stock valued at $14,675,000 after acquiring an additional 384,658 shares in the last quarter. Tekla Capital Management LLC lifted its position in Karyopharm Therapeutics by 25.0% in the 2nd quarter. Tekla Capital Management LLC now owns 756,679 shares of the company’s stock valued at $6,848,000 after acquiring an additional 151,455 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its position in Karyopharm Therapeutics by 25.8% in the 1st quarter. JPMorgan Chase & Co. now owns 518,610 shares of the company’s stock valued at $6,660,000 after acquiring an additional 106,234 shares in the last quarter. 58.97% of the stock is currently owned by institutional investors and hedge funds.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.
Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.